fluorouracil has been researched along with Diabetes Mellitus, Adult-Onset in 15 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 8.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 7.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 7.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 5.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| " CMF, the combination of cyclophosphamide (CYP), methotrexate (MTX), and 5-fluorouracil (5-FU), is employed for the treatment of several types of cancers, such as metastatic breast cancer." | 4.12 | Effects of CMF and MET on glutamate and dopamine levels in the brain, and their impact on cognitive function. ( Abdellatif, AAH; Aldubayan, MA; Alhowail, AH; Almogbel, YS; Chigurupati, S; Nemala, RA, 2022) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 4.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 3.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 3.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "Metformin use was neither associated with OS (adjusted hazard ratio [HR], 1." | 2.90 | Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. ( Adamo, V; Aglietta, M; Antista, M; Banzi, M; Barni, S; Bidoli, P; Buonadonna, A; Cavanna, L; Ciarlo, A; Cinieri, S; Clerico, M; Damiani, A; De Placido, S; Di Bartolomeo, M; Dotti, KF; Faedi, M; Ferrari, D; Ferrari, L; Ferrario, S; Frassineti, GL; Galli, F; Giordani, P; Gori, S; Iaffaioli, RV; Labianca, RF; Leonardi, F; Lonardi, S; Maiello, E; Marchetti, P; Nicolini, M; Pavesi, L; Re, GL; Rosati, G; Tamburini, E; Tronconi, MC; Vernieri, C; Zampino, MG; Zaniboni, A, 2019) |
| "Pancreatic cancer is the fourth leading cause of cancer death in the United States." | 2.45 | Medical management of pancreatic adenocarcinoma. ( Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM, 2009) |
| "Metformin (Met) is a first-line and essential treatment for type 2 diabetes, with anti-inflammatory effects." | 1.72 | Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice. ( Chen, Y; Li, X; Ma, R; Shan, E; Shan, J; Sun, H; Zhang, J; Zhou, Y, 2022) |
| "Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 1.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
| "The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain." | 1.37 | Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 5 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, H | 1 |
| Zhou, Y | 1 |
| Ma, R | 1 |
| Zhang, J | 1 |
| Shan, J | 1 |
| Chen, Y | 1 |
| Li, X | 1 |
| Shan, E | 1 |
| Alhowail, AH | 1 |
| Almogbel, YS | 1 |
| Abdellatif, AAH | 1 |
| Aldubayan, MA | 1 |
| Chigurupati, S | 1 |
| Nemala, RA | 1 |
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, R | 1 |
| Kerr, DJ | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Takei, S | 1 |
| Homma, Y | 1 |
| Matsuyama, R | 1 |
| Endo, I | 1 |
| Bellyei, S | 1 |
| Boronkai, Á | 1 |
| Pozsgai, E | 1 |
| Fodor, D | 1 |
| Mangel, L | 1 |
| Vernieri, C | 1 |
| Galli, F | 2 |
| Ferrari, L | 1 |
| Marchetti, P | 1 |
| Lonardi, S | 1 |
| Maiello, E | 1 |
| Iaffaioli, RV | 1 |
| Zampino, MG | 1 |
| Zaniboni, A | 1 |
| De Placido, S | 1 |
| Banzi, M | 1 |
| Damiani, A | 1 |
| Ferrari, D | 1 |
| Rosati, G | 1 |
| Labianca, RF | 1 |
| Bidoli, P | 1 |
| Frassineti, GL | 1 |
| Nicolini, M | 1 |
| Pavesi, L | 1 |
| Tronconi, MC | 1 |
| Buonadonna, A | 1 |
| Ferrario, S | 1 |
| Re, GL | 1 |
| Adamo, V | 1 |
| Tamburini, E | 1 |
| Clerico, M | 1 |
| Giordani, P | 1 |
| Leonardi, F | 1 |
| Barni, S | 1 |
| Ciarlo, A | 1 |
| Cavanna, L | 1 |
| Gori, S | 1 |
| Cinieri, S | 1 |
| Faedi, M | 1 |
| Aglietta, M | 1 |
| Antista, M | 1 |
| Dotti, KF | 1 |
| Di Bartolomeo, M | 1 |
| Zhang, Y | 1 |
| Guan, M | 1 |
| Zheng, Z | 1 |
| Zhang, Q | 1 |
| Gao, F | 1 |
| Xue, Y | 1 |
| Géresi, K | 1 |
| Megyeri, A | 1 |
| Szabó, B | 1 |
| Szabó, Z | 1 |
| Aradi, J | 1 |
| Németh, J | 1 |
| Benkő, I | 1 |
| Van De Voorde, L | 1 |
| Janssen, L | 1 |
| Larue, R | 1 |
| Houben, R | 1 |
| Buijsen, J | 1 |
| Sosef, M | 1 |
| Vanneste, B | 1 |
| Schraepen, MC | 1 |
| Berbée, M | 1 |
| Lambin, P | 1 |
| Tian, Y | 1 |
| Tang, B | 1 |
| Wang, C | 1 |
| Sun, D | 1 |
| Zhang, R | 1 |
| Luo, N | 1 |
| Han, Z | 1 |
| Liang, R | 1 |
| Gao, Z | 1 |
| Wang, L | 1 |
| Freitas, D | 1 |
| Fernandes, Gdos S | 1 |
| Hoff, PM | 1 |
| Cunha, JE | 1 |
| Feng, YH | 1 |
| Lin, CY | 1 |
| Huang, WT | 1 |
| Wu, CL | 1 |
| Fang, JL | 1 |
| Tsao, CJ | 1 |
| Larsen, ME | 1 |
| Farmer, A | 1 |
| Weaver, A | 1 |
| Young, A | 1 |
| Tarassenko, L | 1 |
| Kanzaki, M | 1 |
| Wada, J | 1 |
| Nakatsuka, A | 1 |
| Teshigawara, S | 1 |
| Murakami, K | 1 |
| Inoue, K | 1 |
| Terami, T | 1 |
| Katayama, A | 1 |
| Nasu, J | 1 |
| Yamamoto, K | 1 |
| Makino, H | 1 |
| Flaherty, AM | 1 |
2 reviews available for fluorouracil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabe | 2009 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
1 trial available for fluorouracil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus, Type 2; F | 2019 |
12 other studies available for fluorouracil and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Metformin protects 5-Fu-induced chemotherapy oral mucositis by reducing endoplasmic reticulum stress in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Diabetes Mellitus, Type 2; Endoplasmic Reticulum Stress; | 2022 |
Effects of CMF and MET on glutamate and dopamine levels in the brain, and their impact on cognitive function.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Breast Neoplasms; Cognition; Cycloph | 2022 |
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne | 2022 |
Hepatectomy for liver metastasis from rectal cancer in a patient with mitochondrial disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diabetes Mellitus, Type 2; Fema | 2021 |
Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diabetes Mell | 2021 |
Effects of metformin on CD133+ colorectal cancer cells in diabetic patients.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Apoptosis; beta | 2013 |
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Diabetes Mellitus, Experimental; | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepato | 2016 |
Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2011 |
Mobile health for drug dose optimisation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Blood Glucose Self-Monitoring; Capecitabine; | 2011 |
A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoproteins.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure | 2012 |